Sambit K. Das

5, KIIT Road
Bhubaneshwar, OR 751024, India

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 83 publications

Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: A phase 3, randomized, active-controlled, multicenter, non-inferiority trial (WIN-IND study).

Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: A phase 3, randomized, active-controlled, multicenter, non-inferiority trial (WIN-IND study).

Journal: Metabolism open
Published: July 16, 2026

Metacrinology.

Metacrinology.

Journal: JPMA. The Journal of the Pakistan Medical Association
Published: May 20, 2026

Non-alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study Assessing Metabolic Indices and Microvascular Complications.

Non-alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study Assessing Metabolic Indices and Microvascular Complications.

Journal: Cureus
Published: May 05, 2026

Comparative Efficacy and Safety of Once-Weekly Semaglutide Formulations in Indian Adults With Obesity: A Phase III, Randomized Non-inferiority Active-Controlled Study (Size Plus Study).

Comparative Efficacy and Safety of Once-Weekly Semaglutide Formulations in Indian Adults With Obesity: A Phase III, Randomized Non-inferiority Active-Controlled Study (Size Plus Study).

Journal: Cureus
Published: March 24, 2026

Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study).

Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study).

Journal: Cardiovascular diabetology. Endocrinology reports
Published: January 28, 2026

Expert Consensus on Obesity Management Protocols - A Joint Position Statement by Obesity and Metabolic Surgery Society of India (OSSI) and Endocrine Society of India (ESI).

Expert Consensus on Obesity Management Protocols - A Joint Position Statement by Obesity and Metabolic Surgery Society of India (OSSI) and Endocrine Society of India (ESI).

Journal: Obesity surgery
Published: January 23, 2026

Treatment Algorithm for Patients with Obesity in India: A Joint Consensus by Endocrine Society of India and Obesity Surgeons Society of India.

Treatment Algorithm for Patients with Obesity in India: A Joint Consensus by Endocrine Society of India and Obesity Surgeons Society of India.

Journal: Obesity surgery
Published: January 20, 2026

A Comparative Evaluation of the Effects of Saroglitazar and Pioglitazone on Hepatic and Metabolic Parameters in Type 2 Diabetes Mellitus With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

A Comparative Evaluation of the Effects of Saroglitazar and Pioglitazone on Hepatic and Metabolic Parameters in Type 2 Diabetes Mellitus With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Journal: Cureus
Published: December 22, 2025

Type 5 diabetes: fifth pillar or fifth column.

Type 5 diabetes: fifth pillar or fifth column.

Journal: JPMA. The Journal of the Pakistan Medical Association
Published: December 19, 2025

Association Between Anthropometric Indices and Presence of Type 2 Diabetes Mellitus in Obesity.

Association Between Anthropometric Indices and Presence of Type 2 Diabetes Mellitus in Obesity.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: December 11, 2025

Endocrine Society of India's National White Paper on Endocrine Disrupting Chemicals - A Call for Action.

Endocrine Society of India's National White Paper on Endocrine Disrupting Chemicals - A Call for Action.

Journal: Indian journal of endocrinology and metabolism
Published: November 08, 2025

Dapagliflozin & pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 study.

Dapagliflozin & pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 study.

Journal: Frontiers in clinical diabetes and healthcare
Published: October 28, 2025
Showing 1-12 of 83

Last Updated: 09/26/2026